Details of the Drug-Related molecule(s) Interaction Atlas

US10065972, Example 560 Drug Info

SCHEMBL18336240; BDBM273119; BDBM273144; BDBM273143; BDBM273093; BDBM273070; US10065972, Example 560; US10065972, Example 265; US10065972, Example 559; US10065972, Example 178; US10065972, Example 347; N-[dideuterio(phenyl)methyl]-1-[7-oxo-5-phenyl-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[6-methyl-7-oxo-5-(2,3,4,5,6-pentadeuteriophenyl)-6,7

Cross-matching ID

PubChem CID

92045015

TTD Drug ID

DM9QCTJ

General Information of Drug (ID: DM9QCTJ)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Kynurenine oxoglutarate transaminase II (AADAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8933095, 1	DMG3T7E	N. A.	N. A.	Patented	[2]
US10065972, Example 281	DMBWJK4	N. A.	N. A.	Patented	[1]
US8933095, 16	DMRN5F4	N. A.	N. A.	Patented	[2]
US10065972, Example 396	DMT8WVZ	N. A.	N. A.	Patented	[1]
US8933095, 18	DMOZ4FS	N. A.	N. A.	Patented	[3]
US8933095, 14	DMZUNJ4	N. A.	N. A.	Patented	[3]
PF-04859989	DM3U2S5	Cognitive impairment	6D71	Preclinical	[4]
BFF-122	DM6BGJ9	Cognitive impairment	6D71	Preclinical	[5]
(S)-4-(Ethylsulfonyl)benzoylalanine	DMEJYV4	Cognitive impairment	6D71	Preclinical	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kynurenine oxoglutarate transaminase II (AADAT)	TTT3IXG	AADAT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Bicyclic or tricyclic heterocyclic compound. US10065972.
2	KAT II inhibitors. US8933095.
3	KAT II inhibitors. US8598200.
4	Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191.
5	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
6	Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009 Mar 3;159(1):196-203.